Vande Woude Laboratory


MET is overexpressed in many types of human cancer, and its expression correlates with aggressive disease and poor prognosis (visit vari.vai.org/met/). Since discovering the MET receptor tyrosine kinase and its ligand, hepatocyte growth factor (HGF/SF), in the mid 1980s, the Vande Woude Laboratory has focused on investigating the paramount role these molecules play in malignant progression and metastasis. As part of the ongoing effort to further our understanding of this signaling system, the lab focuses on the mechanisms responsible for tumor progression under the hypothesis that phenotypic switching and chromosome instability can drive tumor progression. In addition, we continue to develop and characterize novel animal research models that are used in preclinical evaluation of new inhibitors that target MET in a variety of human cancers.